MM-250: Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in the DREAMM-2 Study: 13-Month Follow-Up

CONTEXT: Single-agent belamaf demonstrated deep and durable responses in the DREAMM-2 (NCT03525678) primary analysis (1) and long-term follow-up (2,3). Keratopathy (microcyst-like epithelial changes [MECs] observed on eye examination with/without symptoms) were managed through dose delays and reduct...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Lymphoma Myeloma Leuk
Autori principali: Cohen, Adam D, Lee, Hans C, Trudel, Suzanne, Abdallah, Al-Ola, Callander, Natalie, Libby, Edward, Karlin, Lionel, Lonial, Sagar, Womersley, Lynsey, Baron, January, Lewis, Eric, Nungesser, Katlyn, Gupta, Ira, Opalinska, Joanna
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier Inc. 2020
Soggetti:
Submitted Abstracts
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7832238/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2152-2650(20)30949-6
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi